Actively Recruiting

Phase Not Applicable
Age: 18Years +
FEMALE
ID06739655

Preoperative Radiation Therapy and Immediate Breast Reconstruction in Breast Cancer Patients A Phase 3 Randomized Controlled Trial in the Belgian Population

Led by Cancer Research Antwerp · Updated on 2026-02-04

180

Participants Needed

6

Research Sites

469 weeks

Total Duration

On this page

Sponsors

C

Cancer Research Antwerp

Lead Sponsor

Z

Ziekenhuis aan de Stroom

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are investigating whether giving radiation therapy before breast surgery (mastectomy) combined with immediate breast reconstruction can improve breast appearance and quality of life for women with breast cancer, compared to the current standard treatment where radiation is given after surgery and reconstruction may be delayed. This phase III trial focuses on adult female breast cancer patients who need mastectomy and post-mastectomy radiation therapy (PMRT), aiming to assess satisfaction with breasts, quality of life, aesthetic outcomes, treatment duration, safety, and cancer response over time. Participants are randomly assigned to one of two groups. The control group receives mastectomy followed by postoperative radiation therapy and either immediate or delayed breast reconstruction. The experimental group receives preoperative radiation therapy, then mastectomy with immediate breast reconstruction after 2 to 6 weeks. Radiation therapy follows international guidelines for quality and dosing. Systemic treatments are given as usual by doctors and are not changed by this study. Follow-up visits occur at 3 months, 1, 2, 5, and 10 years after the last treatment, with an intermediate visit at 3 months post-radiation for those with delayed reconstruction. During the study, participants complete questionnaires about breast satisfaction and quality of life, and photographs of the breasts are taken and evaluated by experts. Researchers will track adverse events, cancer response in tissue samples, treatment duration, and cancer recurrence. The study aims to provide detailed information on the benefits and risks of changing radiation timing to improve patient outcomes and quality of life over the long term.

CONDITIONS

Brief Title

Preoperative Radiation Therapy and Immediate Breast Reconstruction

Who Can Participate

Age: 18Years +
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Women aged 18 years or older with confirmed breast cancer
  • Require skin-sparing or nipple-sparing mastectomy
  • Require postoperative radiation therapy of at least the chest wall
  • Desire breast reconstruction
  • Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less
  • Able and willing to provide informed consent and comply with study procedures
Not Eligible

You will not qualify if you...

  • Previous breast cancer or chest wall irradiation on the opposite side
  • Collagen synthesis disease
  • Currently pregnant
  • Actively breastfeeding
  • Smoking at time of inclusion
  • Body mass index greater than 35 kg/m2
  • Tumor classified as cT4d, metastatic disease, or conditions making mastectomy not indicated

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - From randomization until completion of last locoregional treatment, including preoperative radiation therapy (if assigned), surgery, and postoperative radiation therapy (if assigned).

Participants receive either preoperative radiation therapy followed by mastectomy with immediate breast reconstruction, or mastectomy followed by postoperative radiation therapy and immediate or delayed breast reconstruction, depending on randomization.

Multiple visits including radiation therapy sessions and surgical procedures over several weeks

Follow-up

Duration - Up to 10 years after last locoregional treatment

Participants are followed for outcomes including quality of life, satisfaction with breasts, adverse events, and oncological recurrence after completion of treatment.

Visits at 3 months, 1 year, 2 years, 5 years, and 10 years; intermediate follow-up visit at 3 months post-radiation therapy for those with delayed reconstruction

Trial Site Locations

Total: 6 locations

1

Universitair Ziekenhuis Antwerpen (UZA)

Edegem, Antwerpen, Belgium, 2650

Actively Recruiting

2

Ziekenhuis aan de stroom

Wilrijk, Antwerpen, Belgium, 2610

Actively Recruiting

3

AZ Klina

Brasschaat, Antwerp, Belgium, 2930

Not Yet Recruiting

4

CHU Namur

Namur, Namur, Belgium, 5000

Actively Recruiting

5

Universitair Ziekenhuis Gent (UZGent)

Ghent, Oost Vlaanderen, Belgium, 9000

Not Yet Recruiting

6

AZ Groeninge

Kortrijk, West Vlaanderen, Belgium, 8500

Actively Recruiting

Loading map...

Research Team

T

Tom Quisenaerts, MD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

A Phase 2 Trial of (Z)-Endoxifen and Goserelin as Neoadjuvan...

Breast Neoplasms

Actively Recruiting

15 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here